Cargando…

Circulating DNA: Diagnostic Tool and Predictive Marker for Overall Survival of NSCLC Patients

PURPOSE: The purpose of our study was to determine whether the amounts of circulating DNA (cDNA) could discriminate between NSCLC patients and healthy individuals and assess its value as a prognostic marker of this disease. METHODS: We conducted a study of 309 individuals and the cDNA levels were as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Catarino, Raquel, Coelho, Ana, Araújo, António, Gomes, Mónica, Nogueira, Augusto, Lopes, Carlos, Medeiros, Rui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373551/ https://www.ncbi.nlm.nih.gov/pubmed/22701665 http://dx.doi.org/10.1371/journal.pone.0038559

Ejemplares similares

Circulating Ang-2 mRNA Expression Levels: Looking Ahead to a New Prognostic Factor for NSCLC
por: Coelho, Ana L., et al.
Publicado: (2014)

Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?
por: Coelho, Ana Luísa, et al.
Publicado: (2016)

CSF-1 and Ang-2 serum levels — prognostic and diagnostic partners in non-small cell lung cancer
por: Coelho, Ana Luísa, et al.
Publicado: (2018)

Circulating Plasma MicroRNAs As Diagnostic Markers for NSCLC
por: Hou, Jinpao, et al.
Publicado: (2016)

RAD52 Functions in Homologous Recombination and Its Importance on Genomic Integrity Maintenance and Cancer Therapy
por: Nogueira, Augusto, et al.
Publicado: (2019)

The overall survival benefit in Chinese ALK(+) NSCLC patients received targeted therapies
por: Tian, Guangming, et al.
Publicado: (2022)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
por: Ye, Qiuyue, et al.
Publicado: (2023)

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
por: Gray, Jhanelle E., et al.
Publicado: (2019)

Effect of machine learning methods on predicting NSCLC overall survival time based on Radiomics analysis
por: Sun, Wenzheng, et al.
Publicado: (2018)

Increasing Heart Dose Reduces Overall Survival in Patients Undergoing Postoperative Radiation Therapy for NSCLC
por: Shepherd, Annemarie F., et al.
Publicado: (2021)

Combined Influence of EGF+61G>A and TGFB+869T>C Functional Polymorphisms in Renal Cell Carcinoma Progression and Overall Survival: The Link to Plasma Circulating MiR-7 and MiR-221/222 Expression
por: Teixeira, Ana L., et al.
Publicado: (2015)

Construction and Validation of Two Novel Nomograms for Predicting the Overall Survival and Cancer-Specific Survival of NSCLC Patients with Bone Metastasis
por: Dong, Qiu, et al.
Publicado: (2021)

Dynamic Prediction of Near-Term Overall Survival in Patients with Advanced NSCLC Based on Real-World Data
por: Wang, Xuechen, et al.
Publicado: (2022)

Ferroptosis-Related Genes Are Potential Therapeutic Targets and the Model of These Genes Influences Overall Survival of NSCLC Patients
por: Zhang, Na, et al.
Publicado: (2022)

TLR5 Variants Are Associated with the Risk for COPD and NSCLC Development, Better Overall Survival of the NSCLC Patients and Increased Chemosensitivity in the H1299 Cell Line
por: Baranašić, Jurica, et al.
Publicado: (2022)

Mitochondrial markers predict survival and progression in non-small cell lung cancer (NSCLC) patients: Use as companion diagnostics
por: Sotgia, Federica, et al.
Publicado: (2017)

Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis
por: Yan, Weiwei, et al.
Publicado: (2019)

Endothelial dysfunction in diabetes: potential application of circulating markers as advanced diagnostic and prognostic tools
por: Abebe, Worku, et al.
Publicado: (2010)

Nomograms integrating CT radiomic and deep learning signatures to predict overall survival and progression-free survival in NSCLC patients treated with chemotherapy
por: Chang, Runsheng, et al.
Publicado: (2023)

Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer
por: Varkaris, Andreas, et al.
Publicado: (2019)

Circulating MicroRNAs as Potential Biomarkers of Atrial Fibrillation
por: da Silva, Ananília Medeiros Gomes, et al.
Publicado: (2017)

Overall Survival of Nonmetastasized NSCLC Patients Treated With Add-On Viscum album L: A Multicenter Real-World Study
por: Thronicke, Anja, et al.
Publicado: (2020)

Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients
por: Rothschild, S.I., et al.
Publicado: (2021)

Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer
por: Bertorelle, R, et al.
Publicado: (2013)

Analysis of the relation between adverse events and overall survival in patients treated with pembrolizumab as a first-line treatment for metastatic NSCLC
por: Faoro, Lisa, et al.
Publicado: (2023)

Unbiased and Automated Identification of a Circulating Tumour Cell Definition That Associates with Overall Survival
por: Ligthart, Sjoerd T., et al.
Publicado: (2011)

Phenotypic heterogeneity in circulating tumor cells and its prognostic value in metastasis and overall survival
por: Saxena, Kritika, et al.
Publicado: (2019)

10. Circulating Nucleic Acids as Diagnostic Tool
por: Ferrari, Maurizio, et al.
Publicado: (2008)

Monocarboxylate Transporters 1–4 in NSCLC: MCT1 Is an Independent Prognostic Marker for Survival
por: Eilertsen, Marte, et al.
Publicado: (2014)

Markers of Immune Cell Exhaustion as Predictor of Survival in Surgically-Treated Early-Stage NSCLC
por: Sellmer, Laura, et al.
Publicado: (2022)

Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC
por: Goh, Kah Yee, et al.
Publicado: (2023)

Timely Curative Treatment and Overall Mortality Among Veterans With Stage I NSCLC
por: Sanchez, Rolando, et al.
Publicado: (2022)

Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers
por: Navani, Vishal, et al.
Publicado: (2021)

Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations
por: Krawczyk, Paweł, et al.
Publicado: (2015)

Combined Assessment of Preoperative Frailty and Sarcopenia Allows the Prediction of Overall Survival in Patients with Lung Cancer (NSCLC) and Surgically Treated Brain Metastasis
por: Ilic, Inja, et al.
Publicado: (2021)

Tumor markers: A diagnostic tool
por: Nagpal, Madhav, et al.
Publicado: (2016)

The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients
por: Pavo, Noemi, et al.
Publicado: (2019)

Aneuploid subtypes of circulating tumor cells and circulating tumor-derived endothelial cells predict the overall survival of advanced lung cancer
por: Zhang, Jie, et al.
Publicado: (2023)

Circulating microRNAs as Diagnostic Markers in Primary Aldosteronism
por: MacKenzie, Scott M., et al.
Publicado: (2021)

Circulating nucleic acids as a new diagnostic tool
por: Urbanova, Marketa, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_hk5a056grktll10ilja6au0o4h